Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress

Rhea-AI Summary

Enliven Therapeutics (Nasdaq: ELVN) will host a webcast conference call on June 11, 2026 at 8:30 a.m. ET to discuss updated Phase 1 ENABLE clinical trial data for ELVN-001 in previously treated chronic myeloid leukemia, following an oral presentation at the EHA 2026 Congress.

Argus Jun 4 session

-1.50% close to close Open Argus

Details

News Market Reaction – ELVN

On Jun 4, the first trading day after this news, ELVN closed 1.50% below the previous close.

Data tracked by StockTitan Argus for the Jun 4 session.

Market Context

This announcement schedules a webcast on June 11, 2026 to review updated Phase 1 ENABLE data for ELV...

Analysis

This announcement schedules a webcast on June 11, 2026 to review updated Phase 1 ENABLE data for ELVN-001 in chronic myeloid leukemia, coinciding with an EHA 2026 oral presentation. In recent months, the company has highlighted positive Phase 1b results, strong cash of $452.4M, and plans for the ENABLE-2 pivotal trial. Investors may watch the depth of efficacy and safety updates, follow-on development timelines, and any changes to strategy disclosed alongside this presentation.

Key Figures

Webcast date: June 11, 2026 Webcast time ET: 8:30 a.m. ET EHA 2026 dates: June 11–14, 2026 +5 more

Webcast date

June 11, 2026

Company webcast and conference call date

Webcast time ET

8:30 a.m. ET

Start time of company webcast and conference call

EHA 2026 dates

June 11–14, 2026

Duration of EHA 2026 Congress

Oral presentation time

5:45 p.m.–6:00 p.m. CEST

Scheduled EHA oral presentation window on June 11

Oral presentation time ET

11:45 a.m. ET

US Eastern time for EHA oral presentation

Session title code

s416

Chronic myeloid leukemia – Clinical session identifier

Abstract number

S164

EHA 2026 abstract identifier for ENABLE presentation

Hall location

A12 Hall

Physical location of EHA presentation

Historical Context

5 past events · Latest: May 21

5 events

1. May 21

   Investor conferences

   24h Move

   -1.7%

   Participation in upcoming oncology and healthcare investor conferences with webcasts.

2. May 12

   Clinical data update

   24h Move

   +6.8%

   Additional positive Phase 1 ENABLE data for ELVN-001 accepted for EHA 2026 oral.

3. May 07

   Q1 2026 earnings

   24h Move

   +1.1%

   Q1 2026 results with $452.4M cash and plans for Phase 3 ENABLE-2.

4. Mar 03

   FY 2025 earnings

   24h Move

   +4.3%

   Positive initial Phase 1b ELVN-001 data and strong year-end cash position.

5. Feb 25

   Investor conference

   24h Move

   +1.2%

   Announcement of TD Cowen fireside chat with 90-day webcast archive.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

chronic myeloid leukemia, bcr::abl1, cp-cml, atp-competitive inhibitor

4 terms

chronic myeloid leukemia medical

"evaluating ELVN-001 in patients with previously treated chronic myeloid leukemia (CML)"

A cancer of the blood-forming cells in the bone marrow that causes too many abnormal white blood cells to be produced because of a specific genetic change; left untreated it can disrupt normal blood function and the immune system. Investors watch it because the disease has clear biological targets and well-defined treatment pathways, so advances, clinical trial results, regulatory approvals, or pricing shifts for therapies can quickly change the commercial outlook for drug makers — like a new, precision brake applied to an over-revving engine.

bcr::abl1 medical

"a Novel Selective ATP-Competitive Inhibitor of BCR::ABL1, in Patients with Previously Treated CP-CML"

A BCR::ABL1 fusion is a genetic abnormality where parts of two genes join to create a single hybrid gene that makes an abnormal protein driving uncontrolled growth in certain blood cancers. Investors care because this specific, identifiable target determines which drugs and diagnostic tests will work, influencing clinical trial success, drug sales and diagnostic revenue — like finding a particular lock that a new key (therapy) is built to fit.

cp-cml medical

"Inhibitor of BCR::ABL1, in Patients with Previously Treated CP-CML"

cp-cml stands for chronic phase chronic myeloid leukemia, the early and more stable stage of a blood cancer in which abnormal cells grow slowly and symptoms are often milder. It matters to investors because treatments that control or delay progression in this phase can become long-term, high-value products with predictable patient populations and regulatory pathways; think of it like treating a smoldering fire to prevent it becoming a wildfire, which affects market size and revenue predictability.

atp-competitive inhibitor medical

"Updated Efficacy and Safety Results of ELVN-001, a Novel Selective ATP-Competitive Inhibitor of BCR::ABL1"

An ATP-competitive inhibitor is a drug that blocks an enzyme by occupying the same spot where the cell’s energy molecule, ATP, normally binds, preventing the enzyme from working. For investors, this mechanism matters because it influences how potent and selective the drug is, how easily resistance or side effects might arise, and how the therapy will be dosed and positioned commercially—similar to putting the right-shaped key in a lock to stop it from turning.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Enliven will host a webcast conference call on June 11, at 8:30 a.m. ET

BURLINGAME, Calif., June 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that the Company will host a webcast conference call on Thursday, June 11, 2026 at 8:30 a.m. ET to discuss updated data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with previously treated chronic myeloid leukemia (CML) that will be presented at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden, and virtually. The EHA Congress oral presentation will take place on Thursday, June 11, at 5:45 p.m. CEST / 11:45 a.m. ET.

Company webcast and conference call information

Date and time: Thursday, June 11, 8:30 a.m. ET / 2:30 p.m. CEST

Access details: To participate in the live event, please register using this link. Following registration, participants will have access to dial-in numbers and a unique passcode should they prefer to participate by phone. The event and accompanying slides can also be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherapeutics.com/. An archived webcast will be available on the Company's website following the event.

Details of the 2026 EHA oral presentation are as follows:
Title: ENABLE: Updated Efficacy and Safety Results of ELVN-001, a Novel Selective ATP-Competitive Inhibitor of BCR::ABL1, in Patients with Previously Treated CP-CML
Presenter: Dennis Kim, M.D.
Session Title: s416 Chronic myeloid leukemia – Clinical
Location: A12 Hall
Abstract Number: S164
Presentation Date/Time: June 11, 5:45 p.m. - 6:00 p.m. CEST / 11:45 a.m. ET

The abstract is available on the EHA website. Following the EHA oral presentation, a copy will be available on the "Program Presentations & Publications" section of the Company's website at www.enliventherapeutics.com.

About the ENABLE Trial

The ENABLE study (NCT05304377) is a Phase 1 study of ELVN-001 in patients with previously treated CML. ENABLE is a dose escalation and expansion trial designed to evaluate safety and tolerability and to determine the recommended dose for further clinical evaluation of ELVN-001 in patients with CML with and without T315I mutations that is relapsed, refractory or intolerant to tyrosine kinase inhibitors (TKIs). Secondary endpoints include pharmacokinetics, major molecular response (MMR) by central quantitative reverse transcriptase polymerase chain reaction, duration of MMR, BCR::ABL1 transcript levels and complete hematologic response.

About ELVN-001

ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. ELVN-001, a highly selective active-site TKI, has a mechanism of action that is complementary to allosteric BCR::ABL1 inhibitors, which may play an increasingly important role in the standard of care. ELVN-001 was designed to have activity against the T315I mutation, the most common BCR::ABL1 mutation, which confers resistance to nearly all approved TKIs, as well as activity against mutations known to confer resistance to allosteric BCR::ABL1 inhibitors.

About Enliven Therapeutics 

Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights into clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. To learn more, visit www.enliventherapeutics.com and connect with us on LinkedIn and X.

View original content to download multimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-to-host-webcast-conference-call-to-discuss-phase-1-elvn-001-clinical-data-being-presented-at-eha-2026-congress-302790671.html

SOURCE Enliven Therapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Enliven Therapeutics' ELVN-001 webcast for EHA 2026 data (NASDAQ: ELVN)?

The webcast conference call is scheduled for June 11, 2026 at 8:30 a.m. ET. According to Enliven, investors can access the live event by registering online and later replay an archived webcast on the company’s investor relations website.

What ELVN-001 clinical data will Enliven Therapeutics discuss on June 11, 2026?

Enliven will discuss updated Phase 1 ENABLE trial data for ELVN-001 in previously treated chronic myeloid leukemia. According to Enliven, the call follows an EHA 2026 oral presentation covering updated efficacy and safety results of this selective ATP-competitive BCR::ABL1 inhibitor.

How can investors access Enliven Therapeutics' June 11, 2026 ELVN-001 webcast?

Investors can access the live webcast by registering through the provided online link. According to Enliven, registration provides dial-in numbers and a unique passcode, and both the event and slides will be viewable via the investor relations section of its website.

What are the details of Enliven Therapeutics' ELVN-001 oral presentation at EHA 2026?

The oral presentation is on June 11, 2026 from 5:45 p.m. to 6:00 p.m. CEST. According to Enliven, it is titled “ENABLE: Updated Efficacy and Safety Results of ELVN-001” and appears in the chronic myeloid leukemia – clinical session, abstract S164.

Who will present Enliven Therapeutics' ELVN-001 data at the EHA 2026 Congress?

Dennis Kim, M.D., will present the ELVN-001 Phase 1 ENABLE data at EHA 2026. According to Enliven, the talk is part of session s416 on chronic myeloid leukemia – clinical, held in the A12 Hall on June 11, 2026.

Where can I find Enliven Therapeutics' ELVN-001 EHA 2026 abstract and slides?

The ELVN-001 abstract is available on the EHA website before the meeting. According to Enliven, a copy of the oral presentation will be posted after the session in the “Program Presentations & Publications” section of the company’s website.